A new study has found that the use of weight-adjusted Hydroxychloroquine (HCQ) and Azithromycin (AZM) improved the survival of ventilated COVID-19 patients by nearly 200 percent.

The observational study, which has not yet been peer-reviewed, was based on a re-analysis of 255 patients on invasive mechanical ventilation (IMV) during the first two months of the pandemic in the United States.

The researchers found that, when the HCQ/AZM combination was given at lower dosages to treat ventilated COVID-19 patients, the risk of death was over three times higher. Read more from The Epoch Time.